Recce to Attend 11th Annual LifeSci Partners Corporate Access Event
The company is pleased to announce that it will attend the 11th Annual LifeSci Partners Corporate Access Event, being held virtually from January 5th to 7th, 2022.
read full article
Recce tapping European investor interest
Recce listed on the Frankfurt Stock Exchange and is working with German asset manager DGWA as it embarks on a global superbug-fighting strategy.
read full article
AusBiotech Journal 2021 Vol 31
A REVOLUTIONARY APPROACH against antimicrobial resistance
read full article
PharmaShots Interview w Recce CEO James Graham
James Graham, CEO of Recce Pharmaceuticals shared his views on the multiple patient dosing in P-I/II clinical trial of RECCE 327 (R327) for the treatment of infected burn wounds.
read full article
AusBiotech Journal 2020 Vol 30
ADVANCING THE ‘ARMS RACE’ against antibiotic-resistant superbugs
read full article
H.C. Wainwright Global Life Sciences Conference
Click here for full Press Release and Presentation
read full article
Pharmafiles 2020: Synthetic Anti-Infectives
AMR is a ticking time bomb argues Recce CEO James Graham...
read full article
The Australian - Research Special Report 2020
A revolutionary approach to medicine: synthetic anti-Infectives Anti-infectives are used as our frontline treatment for everyday and life threatening bacteria and viral infections…
read full article
Coronavirus crisis
Recce Pharmaceuticals is among dozens of WA-founded biotech companies that are making serious waves in the medical research sector, with COVID-19 the latest disease in its sights...
read full article
Nature Biopharma
New class of synthetic antibiotics set to tackle superbugs PERTH, Australia – A new class of synthetic antibiotics with broad-spectrum activity is being developed by Sydney-based...
read full article
Fighting Antibiotic Resistance
The world needs new classes of antibiotics Antibiotics
The world needs new classes of antibiotics Antibiotics are used as our frontline treatment...
BioWorld
Recce nears clinic with ‘master key’ antibiotic to take on superbugs PERTH, Australia – A new class of synthetic antibiotics with broad-spectrum activity is being developed by Sydney-based...
read full article
The Australian
Australia’s Recce strives for immune-proof super-antibiotic Introductory offers to be billed as follows: The Australian Digital Subscription costs 50c per day, billed monthly (min cost up...
read full article
The West Australian
WA tests synthetic antibiotic A Perth-based pharmaceutical research company is a step closer to developing a new class of synthetic antibiotics to overcome superbugs. Recce Limited has started ...
read full article
S&P Global
Small companies play big role in search for superbug killers Superbugs are quickly becoming a top health concern, yet there has been a roughly 30-year dry spell in antibiotic molecule discovery...
read full article
Sky Business News
Interview with Peter Switzer One of the worrying trends in hospitals are superbugs, raising question marks over the efficacy of antibiotics. Listed company Recce target is targeting this issue ..
read full article
